Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hagen Cramer is active.

Publication


Featured researches published by Hagen Cramer.


Nucleosides, Nucleotides & Nucleic Acids | 2007

2-5A ligands - A new concept for the treatment of prostate cancer

Hagen Cramer; James R. Okicki; Taikyun Rho; Xinning Wang; Robert H. Silverman; Warren D.W. Heston

Several potent prostate specific membrane antigen (PSMA) inhibitors have been described recently. We generated a PSMA-specific 2-5A ligand called RBI 1033 by linking 2-5A to the N-acetylaspartylglutamate (NAAG)-based inhibitor ZJ-24. We measured the inhibitory activity of RBI 1033 to the folate hydrolase activity of PSMA. Amazingly, we found that compared to ZJ-24 (IC50 = 53.9 nM), RBI 1033 was more than 10 times more potent (IC50 = 4.78 nM) as a folate hydrolase inhibitor, while SMCC 2-5A lacking the ZJ-24 part, did not show much activity (IC50 = 1974 nM). Also, RBI 1033s affinity to PSMA was found to be 10 times higher than ZJ-24 itself.


Nucleosides, Nucleotides & Nucleic Acids | 2000

Nucleotides LXIV[1]: Synthesis, Hybridization and Enzymatic Degradation Studies of 2′-O-Methyl-Oligoribonucleotides and 2′-O-Methyl/Deoxy Gapmers

Hagen Cramer; Wolfgang Pfleiderer

Abstract 2′-O-Methyloligoribonucleotides, deoxyoligonucleotides and 2′-O-methyl/ deoxy gapmers were synthesized using solid phase phosphoramidite chemistry employing the 2-(4-nitrophenyl)ethyl (npe) protection strategy. Melting temperatures of the synthesized oligonucleotides as well as their stability against degradation by several different nucleases were determined. 2′-O-Methyloligoribonucleotides showed the highest melting temperatures (Tms) whereas 2′-O-methyl/deoxy gapmers revealed either slightly higher or surprizingly no thermal stabilities compared with their deoxy analogs when using selfcomplementary sequences. Gapmers with four 2′-O-methyl nucleotides on both ends showed about the same stability as all 2′-O-methyloligoribonucleotides against micrococal nuclease, nuclease S1, and snake venom phosphodiesterase.


Nucleosides, Nucleotides & Nucleic Acids | 2005

Targeted therapy of respiratory syncytial virus by 2-5A antisense.

Hagen Cramer; James R. Okicki; Mei Kuang; Zan Xu

Respiratory syncytial virus is a leading cause of respiratory disease in infants, young children, immunocompromized patients, and the elderly. Previous work has shown that RNase L, an antiviral enzyme of the interferon system, can be recruited to cleave RSV genomic RNA by attaching tetrameric 2′-5′-linked oligoadenylates (2 5A) to an antisense oligonucleotide complementary to repetitive intergenic sequences within the RSV genome (2 5A antisense). RBI034, a 2′-O-methyl RNA-modified analogue of the 2 5A anti-RSV compound, was found to have enhanced antiviral activity in cell culture studies while also cleaving RSV genomic RNA in an RNase L· and sequence-specific manner. RBI034′s efficacy in suppressing RSV replication in cell culture is 50 to 100 times better than ribavirin, the only approved drug for RSV infection. Here we show that the activity of 2 5A antisense compound can be further enhanced by a combination treatment with interferon or ribavirin. The anti-RSV activity resulting from combination treatment is more potent than either treatment alone. We also demonstrate that RBI034 is effective against RSV in three different species: mice, cotton rats, and African green monkeys.


Nucleosides, Nucleotides & Nucleic Acids | 2003

The use of triisopropylsilyl-oxymethyl (TOM) in the synthesis of anti-telomerase 2-5A antisense compound RBI 011.

Hagen Cramer; Rachele Rhea; Jim Okicki; Karen Yirava; Robert H. Silverman

Abstract The 2-5A antisense compound RBI 011 targeting telomerase RNA was synthesized using the triisopropylsilyl-oxymethyl (TOM) group for the 3′-hydroxyl protection of 2′,5′-linked RNA.


Nucleosides, Nucleotides & Nucleic Acids | 1999

Using fluorescence resonance energy transfer (FRET) for measuring 2-5A analogues ability to activate RNase L.

Hagen Cramer; Daniel A. Geselowitz; Paul F. Torrence

The development of a method for measuring the ability of 2-5A analogues to activate the cleavage of an oligoribonucleotide substrate by RNase L is described. This method is based on fluorescence resonance energy transfer. The method is easily performed with 96-well plates, allowing for quantitative high-throughput analyses of 2-5A analogues under different reaction conditions.


Nucleosides, Nucleotides & Nucleic Acids | 1997

Synthesis of (2′,5′)-Oligoadenylate Antisense Chimeras Targeting Steroid 5α-Reductase

Hagen Cramer; Paul F. Terrence

Abstract 2–5A antisense chimeras have been synthesized which target human steroid 5α-reductase mRNA. To enhance the stability of the chimera towards degradative enzymes the terminal phosphodiester bond was isomerized from 3′,5′ to 3′,3′ and the 5′-phosphate group was thiolated.


Gynecologic Oncology | 2000

2-5A Antisense Directed against Telomerase RNA Produces Apoptosis in Ovarian Cancer Cells

David M. Kushner; Jayashree M. Paranjape; Bhaswati Bandyopadhyay; Hagen Cramer; Douglas W. Leaman; Alexander W. Kennedy; Robert H. Silverman; John K. Cowell


Archive | 2006

Compounds which bind PSMA and uses thereof

Warren D. W. Heston; Hagen Cramer


Current Medicinal Chemistry | 2001

Chemistry and Biochemistry of 2, 5-Oligoadenylate-Based Antisense Strategy

Steven A. Adah; Suzanne F Bayly; Hagen Cramer; Robert H. Silverman; Paul F. Torrence


Virology | 2002

Targeted Therapy of Respiratory Syncytial Virus in African Green Monkeys by Intranasally Administered 2-5A Antisense

Douglas W. Leaman; Frank J. Longano; James R. Okicki; Kenneth F. Soike; Paul F. Torrence; Robert H. Silverman; Hagen Cramer

Collaboration


Dive into the Hagen Cramer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul F. Torrence

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Mark R. Player

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel A. Geselowitz

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wei Xiao

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge